Mirhoseini M, Shelgikar S, Cayton M M
Heart and Lung Institute of Wisconsin, Milwaukee.
J Clin Laser Med Surg. 1993 Feb;11(1):15-9. doi: 10.1089/clm.1993.11.15.
There is an increasing number of treatment alternatives available for those with ischemic heart disease. Surgical procedures are more sophisticated, a wide array of medications are available, and numerous catheter techniques have evolved to treat patients with coronary artery disease. Technical advances and lifestyle modifications have contributed to a decline in age-adjusted death rates. Despite these advances, there remain a significant number of patients with myocardial ischemia who are not candidates for conventional therapies. Transmyocardial laser revascularization may be a viable adjunct or alternative therapy. In performing this technique, channels are made, from the epicardial surface of the heart through the left ventricle and endocardium, with the CO 2 laser. Perfusion is from the blood supply in the left ventricle via the channels. Postoperative thallium stress tests and left ventriculography indicate that the channels remain patent and protect the ischemic muscle. Experimental and early clinical results of transmyocardial laser revascularization suggest that a group of patients may benefit from this treatment.
对于患有缺血性心脏病的患者,可供选择的治疗方法越来越多。外科手术更加精细复杂,有各种各样的药物可供使用,并且已经发展出许多导管技术来治疗冠状动脉疾病患者。技术进步和生活方式的改变促使年龄调整死亡率下降。尽管有这些进展,但仍有相当数量的心肌缺血患者不适合传统疗法。经心肌激光血运重建术可能是一种可行的辅助或替代疗法。在实施这项技术时,使用二氧化碳激光从心脏的心外膜表面穿过左心室和心内膜制造通道。灌注是通过这些通道来自左心室的血液供应。术后铊负荷试验和左心室造影表明这些通道保持通畅并保护缺血心肌。经心肌激光血运重建术的实验和早期临床结果表明,有一组患者可能会从这种治疗中受益。